EMERYVILLE, Calif., Nov. 01, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at the Stifel 2016 Healthcare Conference in New York on Tuesday, November 15th 2016 at 9:30 a.m. Eastern Time.
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for approximately two weeks.
About Adamas Pharmaceuticals, Inc.
Adamas is a pharmaceutical company that is developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and epilepsy. Adamas has pioneered a platform based on an understanding of time-dependent biologic effects of disease activity and drug response to potentially achieve symptomatic relief without additional tolerability issues. We have developed a portfolio of Chrono-Synchronous Therapies (CSTs) to address chronic neurologic disorders. In addition to ADS-5102, we are investigating ADS-4101 for the improved control of epileptic seizures. Additionally through our license agreement with Forest Laboratories Holding Ltd. (a wholly owned subsidiary of Allergan plc), we are eligible to receive royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Martin Forrest VP Corporate Communications and Investor Relations 510-450-3528


Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



